Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Akero Therapeutics has raised $366.9M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2024.
Akero Therapeutics's investors include General Atlantic, Cormorant Asset Management, Janus Henderson Investors, Adage Capital Management, Perceptive Advisors.
Akero Therapeutics is headquartered in Cambridge, United States.
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Akero Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Akero Therapeutics — Funding & Investors." VCBacked, March 5, 2024, https://www.vcbacked.co/company/akero-therapeutics. Accessed November 13, 2026.
VCBacked. (2024). Akero Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/akero-therapeutics
{{cite web |title=Akero Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/akero-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Akero Therapeutics? Request a listing update